Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Codrux
- Development stage
- Unknown
- Lead developer
- Alben Health Care Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Codrux** is an oral fixed-dose expectorant cough syrup developed and manufactured by Alben Healthcare Industries. Each 5 mL contains diphenhydramine hydrochloride 13 mg, ammonium chloride 100 mg, sodium citrate 40 mg, and menthol 1.1 mg. The formulation combines an H1-antihistamine with expectorant components intended to help relieve cough and chest congestion and to facilitate clearance of respiratory secretions. It was registered in Nigeria on April 4, 2018; the NAFDAC registry lists its registration status as expired as of April 3, 2023. ([greenbook.nafdac.gov.ng](https://greenbook.nafdac.gov.ng/products/details/2441))
- Brand names
- CodruxCodrux Expectorant
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on Codrux.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Codrux.